These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15473338)

  • 1. An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer.
    Sakuma T; Kijima H; Nishi M; Abe Y; Yamazaki H; Mine T; Nakamura M; Ueyama Y
    Tokai J Exp Clin Med; 2004 Jun; 29(2):35-42. PubMed ID: 15473338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells.
    Tsuchida T; Kijima H; Oshika Y; Tokunaga T; Abe Y; Yamazaki H; Tamaoki N; Ueyama Y; Scanlon KJ; Nakamura M
    Biochem Biophys Res Commun; 1998 Dec; 253(2):368-73. PubMed ID: 9878544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer.
    Kijima H; Yamazaki H; Nakamura M; Scanlon KJ; Osamura RY; Ueyama Y
    Int J Oncol; 2004 Mar; 24(3):559-64. PubMed ID: 14767540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma.
    Tsuchida T; Kijima H; Hori S; Oshika Y; Tokunaga T; Kawai K; Yamazaki H; Ueyama Y; Scanlon KJ; Tamaoki N; Nakamura M
    Cancer Gene Ther; 2000 Mar; 7(3):373-83. PubMed ID: 10766343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribozyme as an approach for growth suppression of human pancreatic cancer.
    Kijima H; Scanlon KJ
    Mol Biotechnol; 2000 Jan; 14(1):59-72. PubMed ID: 10911615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line.
    Tokunaga T; Tsuchida T; Kijima H; Okamoto K; Oshika Y; Sawa N; Ohnishi Y; Yamazaki H; Miura S; Ueyama Y; Nakamura M
    Br J Cancer; 2000 Sep; 83(6):833-9. PubMed ID: 10952790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
    Fleming JB; Shen GL; Holloway SE; Davis M; Brekken RA
    Mol Cancer Res; 2005 Jul; 3(7):413-23. PubMed ID: 16046552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells.
    Funato T; Ishii T; Kambe M; Scanlon KJ; Sasaki T
    Cancer Gene Ther; 2000 Mar; 7(3):495-500. PubMed ID: 10766356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Florenes VA; Fodstad O; Scanlon KJ
    Cancer Res; 1994 Feb; 54(4):900-2. PubMed ID: 8313379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity.
    Ohnami S; Matsumoto N; Nakano M; Aoki K; Nagasaki K; Sugimura T; Terada M; Yoshida T
    Cancer Res; 1999 Nov; 59(21):5565-71. PubMed ID: 10554036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
    Qian J; Niu J; Li M; Chiao PJ; Tsao MS
    Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme.
    Feng M; Cabrera G; Deshane J; Scanlon KJ; Curiel DT
    Cancer Res; 1995 May; 55(10):2024-8. PubMed ID: 7743496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ribozyme targeted the point-mutation of activated oncogene inhibits its expression in vivo].
    Liu G; Chen Y; Zhao X; Dong Y; Chen D
    Yi Chuan Xue Bao; 1996; 23(6):477-85. PubMed ID: 9084224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
    Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
    Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
    Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
    Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA.
    Cai DW; Mukhopadhyay T; Roth JA
    Cancer Gene Ther; 1995 Sep; 2(3):199-205. PubMed ID: 8528963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular target-based therapy of pancreatic cancer.
    Lebedeva IV; Sarkar D; Su ZZ; Gopalkrishnan RV; Athar M; Randolph A; Valerie K; Dent P; Fisher PB
    Cancer Res; 2006 Feb; 66(4):2403-13. PubMed ID: 16489047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice.
    Brembeck FH; Schreiber FS; Deramaudt TB; Craig L; Rhoades B; Swain G; Grippo P; Stoffers DA; Silberg DG; Rustgi AK
    Cancer Res; 2003 May; 63(9):2005-9. PubMed ID: 12727809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells.
    Alemany R; Ruan S; Kataoka M; Koch PE; Mukhopadhyay T; Cristiano RJ; Roth JA; Zhang WW
    Cancer Gene Ther; 1996; 3(5):296-301. PubMed ID: 8894248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.